Drug Profile


Alternative Names: fenoximone; MDL 17043; Perfan; Perfan®IV

Latest Information Update: 21 Nov 2006

Price : $50

At a glance

  • Originator sanofi-aventis
  • Class Cardiotonics; Imidazoles; Small molecules; Vasodilators
  • Mechanism of Action Type 3 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Heart failure

Most Recent Events

  • 18 Nov 2006 Myogen has been acquired by Gilead Sciences
  • 07 Feb 2006 Myogen Inc. has sold Myogen GmbH and the sublicense of its rights to intravenous enoximone in markets outside North America, to Wulfing Holding GmbH
  • 28 Jun 2005 Data from a media release have been added to the Heart failure therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top